Key Takeaways
- Tirzepatide, the active ingredient in Eli Lilly’s diabetes drug Mounjaro and obesity medication Zepbound, reduced the risk of heart failure outcomes by 38% versus placebo in a Phase 3 trial.
- Participants also saw a 15.7% reduction in body weight.
- Eli Lilly plans to submit the study results to the FDA later this year.
The active ingredient in Eli Lilly’s (LLY) flagship weight-loss drug has a new potential indication: heart failure treatment.
Tirzepatide, sold as Mounjaro to treat Type 2 diabetes and Zepbound for obesity, reduced the risk of heart failure outcomes by 38% versus placebo in a Phase 3 clinical trial, the company said Thursday.
The SUMMIT trial evaluated the safety and efficacy of the drug in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. In addition to improved heart failure outcomes, participants also saw an average of 15.7% reduction in body weight, compared with 2.2% for placebo.
Eli Lilly said it plans to submit the results of the trial to the Food and Drug Administration (FDA) and other regulators later this year.
Shares of the drugmaker rose nearly 3% to $826.98 as of noon ET Thursday. They are up more than 40% this year.